{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007000","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.259371+00:00","generated_at":"2026-05-17T00:28:31.614518+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart","bullets":["Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).","Austedo revenue $618M (+38% YoY); 2025 outlook raised to $2.05B-$2.15B (from $1.95B-$2.05B).","Non-GAAP operating margin 28.9% (+86 bps YoY); on track for 30% target by 2027.","Exclusive TAPI sale discussions terminated; renewed sales process initiated; divestiture intent maintained.","Full-year 2025 non-GAAP EPS guidance raised to $2.55-$2.65 (midpoint +$0.025); FCF unchanged $1.6B-$1.9B."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007000","json":"https://secwatch.observer/filing/0001171843-25-007000.json","markdown":"https://secwatch.observer/filing/0001171843-25-007000.md","text":"https://secwatch.observer/filing/0001171843-25-007000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/0001171843-25-007000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/f8k_110525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:28:31.614518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}